Latest News - Abbott Laboratories
Top Corporates Hub
Abbott Laboratories
ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
27.05.2026 11:01
Abbott (NYSE: ABT) today announced that the American Cancer Society (ACS) has released updated colorectal cancer (CRC) screening guidelines that reaffirm Cologuard® and Cologuard Plus® as preferred noninvasive screening options for adults age 45 and older who are at average risk for CRC. Both tests are used at a three-year interval.
MMED's Latest Study Supports the Strength of 780G SmartGuard Algorithm
22.05.2026 14:33
MiniMed study results show MiniMed 780G delivering consistent glycemic outcomes across sensors, reinforcing SmartGuard's strength.
Abbott Laboratories (ABT) Slid Due To Its Nutrition Segment’s Sensitivity to Consumer Spending Momentum
22.05.2026 12:55
Carillon Tower Advisers, an investment management company, released its first-quarter 2026 investor letter for the “Carillon Eagle Growth & Income Fund”. A copy of the letter is available to download here. The first quarter of 2026 was volatile due to market shifts, including increased geopolitical risk and inflation fears from rising energy prices. The S&P declined […]
Waiting on Integration Result, Market Stays Moderated on Abbott Laboratories (ABT)
22.05.2026 12:46
Alpha Wealth Funds, LLC, an investment management company, released its Q1 2025 letter for the “Insiders Fund”. A copy of the letter can be downloaded here. The fund lost 7.14% in the quarter, tied to a 6.75% fall in March due to the War in Iran. This compares to the S&P 500’s -4.33% return for […]
Abbott’s Lingo Wearable And Cardio R&D Reframe Long Term Growth Story
22.05.2026 07:15
Abbott Laboratories (NYSE:ABT) is expanding its presence in health tech with new diagnostics and wearable products, including the Lingo biomarker monitoring device. The company is also increasing R&D activity in cardiovascular diagnostics, aiming to broaden its role in earlier detection and ongoing monitoring of heart related conditions. These product moves come as attention on Abbott has recently centered on earnings, insider activity, and the Exact Sciences acquisition rather than its...
Paroxysmal Supraventricular Tachycardia Market Analysis Report 2026-2036, Profiles of Leading Players - Medtronic, Boston Scientific, Abbott Laboratories, Milestone Pharmaceuticals, Sanofi, Pfizer
21.05.2026 13:00
The global Paroxysmal Supraventricular Tachycardia (PSVT) market is set for significant growth, driven by advancements in diagnostics and treatment, and rising cardiovascular awareness. Key factors include a surge in cardiovascular diseases, especially in the aging population, and increased use of minimally invasive techniques like catheter ablation. Emerging economies present ample opportunities, supported by improving healthcare infrastructure and preventive healthcare focus. Challenges persis
Abbott's Biosimilar Push to Help Sustain EPD Growth Momentum
20.05.2026 12:37
ABT's EPD unit posts 9% Q1 sales growth as biosimilars and emerging market demand support its long-term expansion plans.
Abbott Laboratories Insiders Added US$4.23m Of Stock To Their Holdings
19.05.2026 11:00
In the last year, multiple insiders have substantially increased their holdings of Abbott Laboratories ( NYSE:ABT...
The Dip That Keeps On Dipping: 2 Strong Buy Stocks Near 52-Week Lows With 50%+ Upside Potential
19.05.2026 07:30
Discover why BBW and ABT look like undervalued dividend stocks near lows, with ~3% yields, buybacks, and strong upside potentialâread the outlook now.
Tulyp Medical Appoints Industry Veteran Steve Motes as CEO to Lead Next Phase of Growth in the US
18.05.2026 06:00
PARIS & DALLAS, May 18, 2026--Tulyp Medical, a Paris-based medical device company developing an intelligent pressure-driven perfusion system, today announced the appointment of Steve Motes as Chief Executive Officer. The appointment follows positive results from the company’s first-in-human study.
Jim Cramer Compares the Current Selloff in Abbott Labs to the 1999 Market Environment
14.05.2026 15:40
Abbott Laboratories (NYSE:ABT) was one of the stocks on which Jim Cramer shared his take, explaining that dot-com analogies do not hold up in this market. Cramer highlighted it as one of the “greatest American companies,” as he said: …Let’s talk about some similarities that have now been popping up, okay? In 1999, we saw […]
NVision Expands from Quantum Sensing to Quantum Computing to Accelerate Discovery and Validation of New Therapies
13.05.2026 10:00
$55 Million Series B to Advance Quantum for Healthcare Organic molecular crystal containing qubit molecules on a sample holder Organic molecular crystal containing qubit molecules on a sample holder. NVision’s PIQC (“Pixie”) quantum computing platform is designed to integrate these molecule-based qubits as thin layers directly onto photonic chips. This creates a scalable architecture compatible with standard semiconductor manufacturing. ULM, Germany, May 13, 2026 (GLOBE NEWSWIRE) -- NVision, a l
NVision announced a $55 million Series B financing round anchored by Abbott
13.05.2026 07:10
Abbott Laboratories: nVision: announced a $55 million Series B financing round anchored by Abbott nVision: new funding brings nVision's total capital raised to $120 million...
Abbott: Three Supercycles, Mispriced At A 10-Year Low
11.05.2026 10:02
Abbott Laboratories trades at 17.7x forward earnings, the lowest valuation multiple in a decade. Read why I rate ABT stock a Buy right now.
A Look At Abbott Laboratories (ABT) Valuation After Mixed Q1 Results And Baby Formula Legal Ruling
11.05.2026 05:10
Abbott Laboratories (ABT) is back in focus after mixed first quarter results, a cut to its 2026 adjusted EPS outlook tied to the Exact Sciences acquisition, and a large baby formula legal verdict that raised fresh questions. See our latest analysis for Abbott Laboratories. The recent mix of weaker first quarter sentiment, the Exact Sciences related EPS guidance cut and the baby formula verdict has coincided with a sharp reset in expectations. The share price is down 15.9% over 30 days and...
Abbott's Medical Device Strategy Supports Long-Term Growth Outlook
08.05.2026 12:37
ABT's Medical Devices segment posts 8.5% Q1 growth as Electrophysiology, Rhythm Management and Heart Failure deliver strong gains.
Abbott Laboratories (NYSE:ABT) Presents a Decent Value Opportunity After 21% Pullback
08.05.2026 10:10
Abbott Laboratories (ABT) is a top value pick, trading at a discount with strong profitability, financial health, and a 2.78% dividend yield.
Is Abbott Laboratories (ABT) Now Offering Value After Recent Share Price Weakness?
08.05.2026 02:12
If you are wondering whether Abbott Laboratories at around US$87.01 is starting to look like value, the recent share price performance gives you plenty to weigh up. The stock has seen a 4.2% decline over the last week, a 14.6% decline over the last month, and is down 29.9% year to date and 33.7% over the last year. Over the last few months, headlines around Abbott have focused on its position in medical devices and diagnostics, alongside broader sector sentiment that has affected many large...
Abbott Cardiac Data Sheds Light On Heart Rhythm Pipeline And Earnings Story
07.05.2026 09:18
Abbott Laboratories (NYSE:ABT) released new late breaking clinical data on its advanced cardiac devices, focusing on pulsed field ablation and conduction system pacing. The data highlights patient outcomes for the TactiFlex Duo Ablation Catheter, UltiSynq CSP ICD lead, and AVEIR CSP leadless pacemaker in complex heart rhythm disorders. These results add fresh detail on Abbott's electrophysiology and device pipeline beyond its recently covered AI enabled imaging approvals. For anyone...
Breath Analyzer Analysis Report 2026: Market to More than Double to Reach $4.83 Billion by 2030 with Abbott Laboratories, Lifeloc Technologies, and Intoximeters Leading
07.05.2026 08:02
The global breath analyzer market, valued at $1.91 billion in 2024, is projected to reach $4.83 billion by 2030, growing at a CAGR of 16.72%. Key drivers include stringent drunk driving laws, rising demand for non-invasive diagnostics, and growing public safety awareness. Segmentation by technology highlights fuel cell technology as dominant due to its precision and compactness. North America leads the market due to a strong healthcare system and stringent regulations, while Asia Pacific is the